BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today reported financial results for the first quarter of fiscal year 2012 which ended on September 30, 2011.
“We are pleased to have dosed our first patient at Mayo Clinic in our first human clinical study of SNS01-T” Highlights of the first quarter and recent weeks include:
•Initiated patient dosing in its Phase 1b/2a clinical study of SNS01-T •Finalized an agreement with Mayo Clinic to study SNS01-T in multiple myeloma •Selected Criterium, Inc. to manage the operational aspects of Phase 1b/2a clinical study
